Litcius/Paper detail

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial

Robert D. Morgan, Susana Banerjee, Marcia Hall, Andrew R. Clamp, Cong Zhou, Jurjees Hasan, Cecilia Orbegoso, Sarah Taylor, Jonathan Tugwood, Alexander R. Lyon, Caroline Dive, Gordon Rustin, Gordon C. Jayson

2020Gynecologic Oncology24 citationsDOI

Topics & Concepts

PazopanibMedicineTolerabilityInternal medicineDiscontinuationAdverse effectNeutropeniaBevacizumabNauseaRegimenPhases of clinical researchOncologyClinical trialCancerSunitinibChemotherapyOvarian cancer diagnosis and treatmentAngiogenesis and VEGF in CancerPARP inhibition in cancer therapy
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial | Litcius